An Ultra‐Robust and Crystalline Redeemable Hydrogen‐Bonded Organic Framework for Synergistic Chemo‐Photodynamic Therapy

The low structural stability of hydrogen‐bonded organic frameworks (HOFs) is a thorny issue retarding the development of HOFs. A rational design approach is now proposed for construction of a stable HOF. The resultant HOF (PFC‐1) exhibits high surface area of 2122 m2 g−1 and excellent chemical stability (intact in concentrated HCl for at least 117 days). A new method of acid‐assisted crystalline redemption is used to readily cure the thermal damage to PFC‐1. With periodic integration of photoactive pyrene in the robust framework, PFC‐1 can efficiently encapsulate Doxorubicin (Doxo) for synergistic chemo‐photodynamic therapy, showing comparable therapeutic efficacy with the commercial Doxo yet considerably lower cytotoxicity. This work demonstrates the notorious stability issue of HOFs can be properly addressed through rational design, paving a way to develop robust HOFs and offering promising application perspectives. An ultra‐robust hydrogen‐bonded organic framework with high BET surface area and acid‐assisted crystalline recovery was developed through several rational design strategies. With periodic integration of photoactive pyrene in the framework, this material can efficiently encapsulate the drug doxorubicin for synergistic chemo‐photodynamic therapy, showing low cytotoxicity and prominent therapeutic efficacy.